Percutaneous Endocardial Alginate–Hydrogel Injection in the Treatment of Heart Failure: First-in-Human Study
TEAi is feasible and safe for the treatment of HFrEF, warranting further randomized, efficacy clinical trials.
Authors
- Chao Zhu (ORCID: https://orcid.org/0000-0002-6108-985X)
- Ling Tao (ORCID: https://orcid.org/0000-0003-2919-5641)
- R J Lee
- Yunbing Wang (ORCID: https://orcid.org/0000-0002-2412-6762)
- Rutao Wang (ORCID: https://orcid.org/0000-0002-1473-9709)
- Patrick W. Serruys (ORCID: https://orcid.org/0000-0002-9636-1104)
- Shuo Wang (ORCID: https://orcid.org/0000-0002-0990-639X)
- Ying Liu (ORCID: https://orcid.org/0000-0002-8165-9143)
- Xin Meng (ORCID: https://orcid.org/0000-0002-0063-7496)
- Chao Gao (ORCID: https://orcid.org/0000-0001-8904-4875)
- Bo Wang (ORCID: https://orcid.org/0000-0002-7046-2759)
- D. Scott Lim
- Yoshinobu Onuma
Institutions
- Shanghai Medical College of Fudan University (CN)
- University of California, San Francisco (US)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Sichuan University (CN)
- Peking Union Medical College Hospital (CN)
- Chengdu University (CN)
- COPE Galway (IE)
- Shanghai Institute of Computing Technology (CN)
- Xijing Hospital (CN)
- Fu Wai Hospital (CN)
- University of Virginia (US)
- University of San Francisco (US)
- Air Force Medical University (CN)
Publication Details
- Journal
- ESC Heart Failure
- Published
- 2025-10-04
- DOI
- https://doi.org/10.1002/ehf2.15417
- Primary Topic
- Tissue Engineering and Regenerative Medicine
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China